Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

A double-blind placebo controlled study of EGb761 in the treatment of chronic schizophrenia

Meng Fanqiang,et al.Mental Health Institute,Beijing Medical University,Beijing 100083  
Objective:To study the therapeutic effect of shuxuening (EGb761) in chronic schizophrenia.Method:This was a double-blind placebo controlled study. 36 patients with chronic schizophrenia were randomly divided into 2 groups and were given EGb761 and placebo for 8 weeks respectively.BPRS,SANS,CGI and TESS were used to evaluate therapeutic and side effects.Results:EGb761 was significantly superior to placebo according to CGI and SANS scores.No difference in side effect was found between the 2 groups at recommended dosage (EGb761 80mg tid).After finishing the 8-week trial,2 subjects were given an increased dosage of EGb761 (160mg tid) for another 2 weeks,but they developed new positive symptoms.Discussion:Within a specific dosage range,EGb761 is clinically effective for reducing the negative symptoms of schizophrenia.But it seems not to have effect on positive symptoms.Further studies of longer period of treatment are needed to address this issue.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved